CA3111908A1 - Methodes et compositions pour l'administration d'agents actifs d'acide mycophenolique a des mammiferes non humains - Google Patents
Methodes et compositions pour l'administration d'agents actifs d'acide mycophenolique a des mammiferes non humains Download PDFInfo
- Publication number
- CA3111908A1 CA3111908A1 CA3111908A CA3111908A CA3111908A1 CA 3111908 A1 CA3111908 A1 CA 3111908A1 CA 3111908 A CA3111908 A CA 3111908A CA 3111908 A CA3111908 A CA 3111908A CA 3111908 A1 CA3111908 A1 CA 3111908A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- subject
- mpa
- hours following
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title claims abstract description 403
- 229960000951 mycophenolic acid Drugs 0.000 title claims abstract description 390
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 title claims abstract description 353
- 239000000203 mixture Substances 0.000 title claims abstract description 214
- 239000013543 active substance Substances 0.000 title claims abstract description 143
- 238000000034 method Methods 0.000 title claims abstract description 128
- 241000282465 Canis Species 0.000 claims abstract description 122
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 39
- 238000013270 controlled release Methods 0.000 claims description 165
- 210000004698 lymphocyte Anatomy 0.000 claims description 154
- 238000009472 formulation Methods 0.000 claims description 128
- 210000004369 blood Anatomy 0.000 claims description 117
- 239000008280 blood Substances 0.000 claims description 117
- 230000002062 proliferating effect Effects 0.000 claims description 106
- 239000010410 layer Substances 0.000 claims description 97
- 230000002829 reductive effect Effects 0.000 claims description 61
- 206010012735 Diarrhoea Diseases 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 51
- 230000002496 gastric effect Effects 0.000 claims description 48
- 230000035755 proliferation Effects 0.000 claims description 46
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 42
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 40
- 230000002411 adverse Effects 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 36
- 206010047700 Vomiting Diseases 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 24
- 239000011241 protective layer Substances 0.000 claims description 23
- 239000002775 capsule Substances 0.000 claims description 20
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 16
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 16
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 16
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 16
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 16
- 239000007943 implant Substances 0.000 claims description 14
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 14
- 230000001594 aberrant effect Effects 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 13
- 210000000056 organ Anatomy 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 9
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 206010015218 Erythema multiforme Diseases 0.000 claims description 8
- 206010015226 Erythema nodosum Diseases 0.000 claims description 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 8
- 208000003807 Graves Disease Diseases 0.000 claims description 8
- 208000015023 Graves' disease Diseases 0.000 claims description 8
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 8
- 206010033661 Pancytopenia Diseases 0.000 claims description 8
- 201000011152 Pemphigus Diseases 0.000 claims description 8
- 206010039710 Scleroderma Diseases 0.000 claims description 8
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 8
- 206010047112 Vasculitides Diseases 0.000 claims description 8
- 206010047115 Vasculitis Diseases 0.000 claims description 8
- 206010047642 Vitiligo Diseases 0.000 claims description 8
- 208000007502 anemia Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 208000024389 cytopenia Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000002949 hemolytic effect Effects 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 201000011486 lichen planus Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 206010028417 myasthenia gravis Diseases 0.000 claims description 8
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 8
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 201000000306 sarcoidosis Diseases 0.000 claims description 8
- 208000015943 Coeliac disease Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 239000008298 dragée Substances 0.000 claims description 6
- 208000009137 Behcet syndrome Diseases 0.000 claims description 5
- 238000012377 drug delivery Methods 0.000 claims description 5
- 208000014951 hematologic disease Diseases 0.000 abstract description 4
- 208000019838 Blood disease Diseases 0.000 abstract description 3
- 208000018706 hematopoietic system disease Diseases 0.000 abstract description 3
- 239000011324 bead Substances 0.000 description 109
- 241000282472 Canis lupus familiaris Species 0.000 description 75
- 210000002381 plasma Anatomy 0.000 description 70
- 229940079593 drug Drugs 0.000 description 47
- 238000000576 coating method Methods 0.000 description 41
- 239000011248 coating agent Substances 0.000 description 40
- 208000002447 Macrophagic myofasciitis Diseases 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- 230000003285 pharmacodynamic effect Effects 0.000 description 36
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 31
- 229920000642 polymer Polymers 0.000 description 28
- 238000011282 treatment Methods 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 239000012530 fluid Substances 0.000 description 23
- 229920001249 ethyl cellulose Polymers 0.000 description 21
- 235000019325 ethyl cellulose Nutrition 0.000 description 21
- -1 homologs Chemical class 0.000 description 20
- 239000001856 Ethyl cellulose Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 230000036470 plasma concentration Effects 0.000 description 16
- 239000008213 purified water Substances 0.000 description 16
- 229920003134 Eudragit® polymer Polymers 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000006185 dispersion Substances 0.000 description 14
- 239000000454 talc Substances 0.000 description 14
- 229910052623 talc Inorganic materials 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 13
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 12
- 239000002207 metabolite Substances 0.000 description 12
- 230000009467 reduction Effects 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008185 minitablet Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000001069 triethyl citrate Substances 0.000 description 8
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 8
- 235000013769 triethyl citrate Nutrition 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000002702 enteric coating Substances 0.000 description 7
- 238000009505 enteric coating Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000000737 periodic effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 241000282421 Canidae Species 0.000 description 5
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 5
- 102000009875 Ki-67 Antigen Human genes 0.000 description 5
- 108010020437 Ki-67 Antigen Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000002051 biphasic effect Effects 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000013265 extended release Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 229940014456 mycophenolate Drugs 0.000 description 5
- 229920000058 polyacrylate Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 description 4
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940100692 oral suspension Drugs 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 3
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000013029 homogenous suspension Substances 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000009498 subcoating Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- AWKYSZSJPJUFQS-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1NC(=O)NC2=C1NC=N2 AWKYSZSJPJUFQS-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241001463143 Auca Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920003136 Eudragit® L polymer Polymers 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- RTGDFNSFWBGLEC-UHFFFAOYSA-N Mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229940107810 cellcept Drugs 0.000 description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011362 coarse particle Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000013481 data capture Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000028659 discharge Diseases 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229920003125 hypromellose 2910 Polymers 0.000 description 2
- 229940031672 hypromellose 2910 Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000005722 itchiness Effects 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000189662 Calla Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001044118 Homo sapiens Inosine-5'-monophosphate dehydrogenase 1 Proteins 0.000 description 1
- 101001076642 Homo sapiens Inosine-5'-monophosphate dehydrogenase 2 Proteins 0.000 description 1
- 101001023733 Homo sapiens Neurotrypsin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100021602 Inosine-5'-monophosphate dehydrogenase 1 Human genes 0.000 description 1
- 102100025891 Inosine-5'-monophosphate dehydrogenase 2 Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 206010028124 Mucosal ulceration Diseases 0.000 description 1
- 101001033610 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100035484 Neurotrypsin Human genes 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- ZUPXXZAVUHFCNV-UHFFFAOYSA-N [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;potassium Chemical compound [K].C1=CCC(C(=O)N)=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OCC2C(C(O)C(O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ZUPXXZAVUHFCNV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940083410 myfortic Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des méthodes et des compositions pour l'administration modifiée d'agents actifs d'acide mycophénolique, notamment du mycophénolate de sodium, chez des sujets canins. Les méthodes et compositions selon l'invention sont utiles, par exemple, pour traiter des maladies auto-immunes, des troubles sanguins associés et un rejet immunitaire lié à des interventions de greffe ou de transplantation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/050079 WO2020050863A1 (fr) | 2018-09-07 | 2018-09-07 | Méthodes et compositions pour l'administration d'agents actifs d'acide mycophénolique à des mammifères non humains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3111908A1 true CA3111908A1 (fr) | 2020-03-12 |
Family
ID=63684613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3111908A Abandoned CA3111908A1 (fr) | 2018-09-07 | 2018-09-07 | Methodes et compositions pour l'administration d'agents actifs d'acide mycophenolique a des mammiferes non humains |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3846798A1 (fr) |
| JP (1) | JP2022506007A (fr) |
| CA (1) | CA3111908A1 (fr) |
| WO (1) | WO2020050863A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4808413A (en) | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
| US5049394A (en) | 1987-09-11 | 1991-09-17 | E. R. Squibb & Sons, Inc. | Pharmaceutical composition containing high drug load and method for preparing same |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| CN1994295A (zh) * | 2006-01-06 | 2007-07-11 | 华北制药集团新药研究开发有限责任公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
| EA201071035A1 (ru) * | 2008-03-05 | 2011-04-29 | Панацеа Биотек Лимитед | Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения |
| KR20110091252A (ko) * | 2010-02-05 | 2011-08-11 | 서울대학교산학협력단 | 미코페놀레이트 모페틸을 함유한 서방성 면역 억제제 |
| CN103845323B (zh) * | 2012-11-30 | 2018-02-02 | 重庆华邦制药有限公司 | 麦考酚酸及其盐肠溶制剂和制备方法 |
| AU2018236225B2 (en) * | 2017-03-13 | 2023-11-30 | Okava Pharmaceuticals, Inc. | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals |
| CN108066322A (zh) * | 2018-02-01 | 2018-05-25 | 宁波蒙曼生物科技有限公司 | 一种吗替麦考酚酯缓释胶囊及其制备方法 |
-
2018
- 2018-09-07 JP JP2021512709A patent/JP2022506007A/ja active Pending
- 2018-09-07 CA CA3111908A patent/CA3111908A1/fr not_active Abandoned
- 2018-09-07 WO PCT/US2018/050079 patent/WO2020050863A1/fr unknown
- 2018-09-07 EP EP18778780.9A patent/EP3846798A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020050863A1 (fr) | 2020-03-12 |
| EP3846798A1 (fr) | 2021-07-14 |
| JP2022506007A (ja) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6558704B1 (en) | Process for preparing pellets containing up to 90 wt.% of a pharmaceutical active ingredient | |
| JP2008303223A (ja) | 脈動用量薬剤経口送達システム | |
| CN108066319B (zh) | 一种枸橼酸托法替布肠溶缓释微丸及其制备方法 | |
| BRPI0714915A2 (pt) | composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica | |
| MXPA06003602A (es) | Formulaciones de microparticulas de pantoprazol. | |
| KR20080007252A (ko) | 양성 전립선 과다형성증용 치료 조합물 | |
| US20240299343A1 (en) | Methods and compositions for delivering mycophenolic acid active agents to non-human mammals | |
| US7192608B2 (en) | Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules | |
| US20090311317A1 (en) | Modified release tolterodine formulations | |
| CN102046155A (zh) | 包含多颗粒的具有双重释放特性的固体口服剂型 | |
| KR102276896B1 (ko) | 파킨슨병의 고정용량 조합 치료법 | |
| AU2008365126A1 (en) | Tamsulosin pellets for fixed dose combination | |
| US20090130202A1 (en) | Pharmaceutical Compositions | |
| CA3111908A1 (fr) | Methodes et compositions pour l'administration d'agents actifs d'acide mycophenolique a des mammiferes non humains | |
| CN102579392A (zh) | 一种含有盐酸坦索罗辛的缓释制剂及其制备方法 | |
| US20080193537A1 (en) | Morphine Sulfate Formulations | |
| EP1784161B1 (fr) | Formulation à libération contrôlée comprenant de l'hydrochlorure de tamsulosine | |
| RU2584653C2 (ru) | Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения | |
| CN114432257B (zh) | 一种艾氟洛芬缓释片剂及其制备方法 | |
| TR201802243T4 (tr) | Vildagliptin ve gliklazid kombinasyon kompozisyonu. | |
| Hadi et al. | Design and in-vitro evaluation of multiparticulate drug delivery system of terbutaline sulphate for the treatment of nocturnal asthma | |
| KR20230152051A (ko) | 멜라토닌을 포함하는 다층 펠릿의 제형(formulation of a multilayered pellet comprising melatonin) | |
| US20120107393A1 (en) | Pellets for Delivery of Biologically Active Substances | |
| NZ718686A (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
| NZ718686B2 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20240307 |